Fujian Shengdi Pharmaceutical Co., Ltd.

This early-stage study tests two versions of an experimental tablet called HRS9531 in 168 overweight or obese men aged 18-55. The main goal is to compare how the body absorbs each version and to check for side effects. Participants must have a stable weight and a BMI between 24 a…

This study tests a new medicine, HRS-7249, to see if it can safely lower high levels of fats called triglycerides in the blood. About 200 adults with hyperlipidemia will receive either the drug or a placebo. The goal is to find the best dose and check for side effects.

This study tests a new medicine called HRS-9563 in 234 adults with mild to moderate high blood pressure. Half will get the drug, half a placebo, to see if it safely lowers blood pressure over 6 months. The goal is to find the right dose for better blood pressure control.

This study tests a new drug called HRS9531 to see if it helps people with type 2 diabetes who are not getting enough blood sugar control from their current insulin. About 300 adults will receive either HRS9531 or a placebo for 40 weeks. The main goal is to measure changes in bloo…

This study tests two experimental drugs, HRS-7249 and SHR-1918, in 108 adults with dangerously high triglycerides who are at risk for acute pancreatitis. The goal is to see if the drugs can safely lower fat levels in the blood and reduce the chance of a pancreatitis attack. Parti…

This study tests an experimental injection called HRS-5635, given alone or with other drugs, in 369 adults with chronic hepatitis B whose virus is already suppressed by standard pills. The main goal is to lower or clear a key virus marker (HBsAg) from the blood. Participants must…

This study tests an injection called HRS9531 for people with obstructive sleep apnea (OSA) and obesity who do not use a breathing machine (PAP therapy). The goal is to see if the drug can reduce breathing pauses during sleep and help with weight loss. About 140 adults aged 18-75 …

This study tests an injectable drug called HRS9531 in people with moderate-to-severe obstructive sleep apnea (OSA) and obesity who already use a breathing machine (PAP) at night. The goal is to see if the drug reduces breathing pauses during sleep and helps with weight loss. Abou…

This early-stage study tests a new drug called HRS-5817, given as an injection, to see if it is safe and how the body processes it. The study involves 92 healthy adults, some with obesity and some without. Researchers will monitor side effects and measure drug levels in the blood…

This study tests an experimental drug called HRS-7450 in 208 people who have had an acute ischemic stroke. Participants must start treatment between 4.5 and 24 hours after symptoms begin. The main goal is to see if the drug helps patients achieve a good recovery (little or no dis…

This early-stage study is testing a single injection of HRS-2162 in 64 healthy adults aged 18 to 45. The main goal is to check if the drug is safe and to see how the body absorbs and processes it. This research is a first step toward developing a treatment that could reverse musc…

This study tests an injectable drug called HRS-9057 in adults hospitalized with heart failure who have fluid retention. The main goal is to see if it helps reduce weight (a sign of fluid loss) by day 8 compared to a placebo. About 153 participants will receive either the drug or …